**Promising Results for Seralutinib in Pulmonary Arterial Hypertension** A recent international study shows that the new drug Seralutinib significantly reduces symptoms of pulmonary arterial hypertension, especially in advanced stages. This development offers new hope for...
An interdisciplinary team at JLU has unveiled genetic networks involved in right heart failure, a condition closely tied to lung diseases. Their research offers new insights and potential treatment targets for this severe illness.
The German Research Foundation (DFG) has approved the third funding period for the Giessen Collaborative Research Centre 1213 on cardiopulmonary research - the researchers led by DZL scientist Prof. Dr Norbert Weißmann can thus build...
DZL scientist Prof. Dr. Soni Savai Pullamsetti and her team have discovered signalling pathways involved in developing right heart failure in patients with pulmonary hypertension. The findings provide new biomarkers for diagnosis and targets for...
The National Academy of Sciences Leopoldina is Germany's oldest scientific and medical-learned society. DZL researcher Prof. Pullamsetti was admitted to the prestigious Leopoldina.
DZL researchers have found that inhibiting a signaling pathway reduces pathological remodeling of the right ventricle in pulmonary hypertension.
DZL researchers at Helmholtz Munich and their collaborators developed the Human Lung Cell Atlas using artificial intelligence (AI)-based techniques. This atlas elucidates the diversity of single lung cell types and allows learning about lung biology...
DZL scientists identified a new player within the pressure regulation in pulmonary vessels
Further funding of clinical studies by the DZL in 2022. Two studies were successful in this year's application round.
DZL scientists discover novel, attractive therapeutic strategy to treat PH with an active ingredient from the walnut.
The DZL Annual Report 2020 has been published in German and English and is now available from the Media Center.
Pulmonary hypertension is a common co-morbidity of COPD. Previous studies have already established that (in the experimental model) pulmonary vascular changes precede the development of emphysema.
